Last reviewed · How we verify

Mahmoud I Mostafa — Portfolio Competitive Intelligence Brief

Mahmoud I Mostafa pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Polymyxin e Polymyxin e marketed Polymyxin antibiotic Bacterial lipopolysaccharides and phospholipids Infectious Disease

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 1 shared drug class
  2. Hospitales Universitarios Virgen del Rocío · 1 shared drug class
  3. King Saud Medical City · 1 shared drug class
  4. Merck Sharp & Dohme LLC · 1 shared drug class
  5. Vanderbilt University Medical Center · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Mahmoud I Mostafa:

Cite this brief

Drug Landscape (2026). Mahmoud I Mostafa — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/mahmoud-i-mostafa. Accessed 2026-05-16.

Related